Korro Bio (NASDAQ:KRRO) Given “Outperform” Rating at William Blair

Korro Bio (NASDAQ:KRRO)‘s stock had its “outperform” rating reaffirmed by analysts at William Blair in a report released on Wednesday,RTT News reports.

A number of other research firms have also recently commented on KRRO. Royal Bank of Canada raised their price target on Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Monday, October 21st. HC Wainwright boosted their price target on Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, Raymond James initiated coverage on shares of Korro Bio in a report on Monday, October 21st. They set a “strong-buy” rating and a $153.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $142.17.

Korro Bio Stock Down 9.7 %

NASDAQ KRRO opened at $49.70 on Wednesday. Korro Bio has a 52 week low of $30.00 and a 52 week high of $98.00. The stock’s 50-day moving average price is $49.77 and its 200-day moving average price is $46.92.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.55) by $0.29. On average, research analysts anticipate that Korro Bio will post -10.02 EPS for the current fiscal year.

Insider Buying and Selling

In other Korro Bio news, CFO Vineet Agarwal sold 800 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $70.00, for a total transaction of $56,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of Korro Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new position in shares of Korro Bio during the second quarter valued at approximately $649,000. Rhumbline Advisers purchased a new position in Korro Bio during the 2nd quarter valued at $279,000. Atlas Venture Life Science Advisors LLC grew its position in Korro Bio by 1.6% in the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock valued at $38,515,000 after acquiring an additional 17,857 shares during the last quarter. Brown Brothers Harriman & Co. purchased a new stake in Korro Bio in the second quarter worth $28,000. Finally, Tri Locum Partners LP bought a new stake in shares of Korro Bio during the second quarter worth $2,419,000. 13.18% of the stock is owned by hedge funds and other institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).